NCT00183872 - Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 14, 2005

Primary Completion Date

October 20, 2014

Study Completion Date

October 20, 2015

Conditions

Gastric CancerEsophageal Neoplasms

Interventions

DRUG

irinotecan, docetaxel

docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.

Trial Locations (1)

University of Southern California (U.S.C.)/ Norris Comprehensive Cancer Center, Los Angeles